Related Experiment Video

Updated: Oct 14, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.0K

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study

Alessia Mennitto1, Emma Zattarin1, Massimo Di Maio2

  • 1Department of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy.

Expert Review of Anticancer Therapy
|November 5, 2021
PubMed
Abstract

Insights

Continuing cabozantinib after disease progression in metastatic renal cell carcinoma (mRCC) significantly improved postprogression survival (PPS). This strategy offers a promising option for patients with advanced kidney cancer.

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Cabozantinib is a known treatment for metastatic renal cell carcinoma (mRCC) after antiangiogenic therapies.
  • Optimal treatment strategies upon disease progression (PD) in mRCC remain unclear.
  • Cabozantinib's AXL/MET inhibitory activity suggests potential for overcoming acquired resistance.

Purpose of the Study:

  • To evaluate the efficacy of continuing cabozantinib beyond PD in mRCC patients.
  • To compare postprogression survival (PPS) between patients who continued cabozantinib and those who switched therapy.

Main Methods:

  • Retrospective multicenter study of 89 mRCC patients treated between 2014-2020.
  • Comparison of patients maintaining cabozantinib post-PD versus those switching therapy.
  • Primary endpoint: Postprogression survival (PPS).

Main Results:

  • Patients continuing cabozantinib (n=45) had longer median PPS (16.9 months) than those switching (n=44, 13.2 months).
  • Continuing cabozantinib was associated with a significantly longer PPS (HR 0.66, p=0.011).
  • Patients continuing cabozantinib demonstrated a higher response rate before PD (46.7% vs 25%, p=0.03).

Conclusions:

  • Continuing cabozantinib beyond PD in mRCC patients is associated with improved postprogression survival.
  • This approach represents a potentially effective treatment option for selected patients.
  • Further investigation into cabozantinib's role in managing acquired resistance in mRCC is warranted.
Keywords:
Cabozantinibkidney cancer treatmentmetastatic renal cell carcinomapost-progression survivaltreatment beyond progression

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K